Search
IPH 1101
go.drugbank.com/drugs/DB05754ExperimentalIPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.
T-5224
go.drugbank.com/drugs/DB05998ExperimentalT-5224 is an investigational drug developed to treat Sepsis-induced Acute Kidney Injury. It's mechanism of action is to inhibit c-Fos/activator protein-1.
FAV-201
go.drugbank.com/drugs/DB06130ExperimentalFAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.
Mesmulogene ancovacivec
go.drugbank.com/drugs/DB06584InvestigationalVaccination with MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen,
Radium Ra-223
go.drugbank.com/drugs/DB12813InvestigationalRadium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).
Silicon
go.drugbank.com/drugs/DB12982ApprovedSilicon is under investigation in clinical trial NCT00103246 (Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides).
Mixtures: Advanced B & T FormulaLysozyme
go.drugbank.com/drugs/DB13260InvestigationalMixtures: E-zyme B6 Troche, E-zyme B6 Soothing LiquidProducts: Leftose 30mg Tablet, NEUFLO TABLET 90MGSodium molybdate
go.drugbank.com/drugs/DB14496ApprovedSynonyms: Molybdenum (as sodium)Mixtures: Advanced B & T FormulaCerdulatinib
go.drugbank.com/drugs/DB15499InvestigationalCerdulatinib is under investigation in clinical trial NCT04021082 (CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/refractory Peripheral T-cell Lymphoma (PTCL)).
OBI-3424
go.drugbank.com/drugs/DB16057InvestigationalOBI-3424 is under investigation in clinical trial NCT04315324 (Study to Test Akr1c3-activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/refractory T-cell Acute Lymphoblastic Leukemia (T-ALL